Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
about
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics
P2860
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Simultaneous population pharma ...... ent dose reduction strategies.
@ast
Simultaneous population pharma ...... ent dose reduction strategies.
@en
type
label
Simultaneous population pharma ...... ent dose reduction strategies.
@ast
Simultaneous population pharma ...... ent dose reduction strategies.
@en
prefLabel
Simultaneous population pharma ...... ent dose reduction strategies.
@ast
Simultaneous population pharma ...... ent dose reduction strategies.
@en
P2093
P2860
P1476
Simultaneous population pharma ...... ent dose reduction strategies.
@en
P2093
Alessandro Schipani
David Back
Gerry Davies
Laura Dickinson
Marta Boffito
Rupert Austin
P2860
P356
10.1097/QAI.0B013E3182737231
P407
P50
P577
2013-01-01T00:00:00Z